Paraquat Poisoning: Management

Background

Mechanism of Toxicity

• Paraquat undergoes intracellular redox cycling, generating reactive oxygen species (ROS) — particularly superoxide radicals.
• This causes lipid peroxidation of cell membranes, leading to massive oxidative stress.
• Lung is the primary target: paraquat is actively concentrated in type I and II pneumocytes via polyamine transport, causing progressive alveolitis and ultimately pulmonary fibrosis.
• Kidneys are the second major target; hepatic and adrenal damage also occur.

Clinical Phases

• Dermal/inhalation exposure: less absorbed; usually milder, but concentrated solution on intact skin can be fatal.
• Nail changes: Leukonychia or nail discoloration (white bands) may appear later.

Severity Assessment

Plasma Paraquat Level

• Levels above the survival line = poor prognosis
• Even moderate levels (>3 mg/L at 4 hours) carry high mortality

APACHE II / Severity Scores

• Ingestion of >40 mg/kg: near uniformly fatal
• 20–40 mg/kg: severe toxicity, possible survival with aggressive treatment
• <20 mg/kg (confined herbicide): possible survival

Management Principles

1. Decontamination (Minimize Absorption)

Time is critical: every hour of delay reduces efficacy of decontamination.

2. Enhance Elimination

Hemoperfusion is preferred over hemodialysis for paraquat removal; however, its benefit on mortality is uncertain given rapid tissue distribution.

3. Minimize Oxidative Injury (Experimental/Adjunctive)

4. Immunosuppression Protocol (For Moderate Toxicity)

• Methylprednisolone: 1 g IV daily × 3 days, then taper
• Cyclophosphamide: 15 mg/kg IV on days 1 and 2

Evidence is moderate quality, but this is a reasonable attempt given the otherwise grim prognosis. Avoid if overwhelming ingestion (futile).

5. AVOID SUPPLEMENTAL OXYGEN

Critical: Supplemental oxygen dramatically accelerates ROS generation and pulmonary injury.

• Keep SpO₂ at 90–92% (not higher) using the minimum FiO₂ necessary.
• Avoid high-flow oxygen unless the patient is in imminent respiratory failure.
• Mechanical ventilation is generally a terminal event in severe paraquat poisoning.

6. Supportive Care

• IV fluids: maintain renal perfusion; avoid overload
• Analgesia: oropharyngeal burns are extremely painful (opioids may be needed)
• Nutritional support: enteral feeding via NGT/NJT if oral intake is impossible due to mucosal burns
• Mouth care: oropharyngeal ulcers require meticulous oral hygiene
• Renal replacement therapy: for established AKI
• Monitor: LFTs, creatinine, electrolytes, ABG, daily CXR

7. Lung Transplantation

• Has been attempted in a small number of cases; most patients die post-transplant due to ongoing paraquat distribution to the new lung or systemic toxicity.
• Generally considered contraindicated unless paraquat has been fully eliminated (confirmed by undetectable plasma/urine levels).

Prognosis

Summary Algorithm

Paraquat ingestion suspected
        ↓
Decontaminate immediately
(Fuller's earth / activated charcoal, skin wash)
        ↓
Establish plasma paraquat level + urine dithionite test
        ↓
Hemoperfusion ASAP (within 4–8 hours)
        ↓
Avoid oxygen supplementation (SpO₂ target 90–92%)
        ↓
Immunosuppression (methylprednisolone + cyclophosphamide)
        ↓
Antioxidants (NAC, Vitamin C/E)
        ↓
Supportive care (AKI management, nutrition, analgesia)
        ↓
Monitor: renal, hepatic, pulmonary function daily

Management of High Triglycerides (Hypertriglyceridemia)

Classification

Step 1: Identify and Treat Secondary Causes

Step 2: Lifestyle Modification (First-Line for All)

• Dietary fat restriction: reduce saturated and trans fats; replace with unsaturated fats
• Refined carbohydrate restriction: limit sugar, white bread, sweetened beverages — these directly drive hepatic TG synthesis
• Alcohol cessation: alcohol is one of the most potent drivers of elevated TGs; even moderate intake can significantly raise levels
• Weight loss: 5–10% body weight reduction significantly lowers TGs
• Aerobic exercise: 30–60 minutes of moderate-intensity exercise most days
• Low-glycemic diet: Mediterranean or low-carbohydrate diet patterns are particularly effective

TGs are more responsive to dietary modification than LDL cholesterol.

Step 3: Pharmacotherapy

When to initiate:

• TG ≥ 500 mg/dL: pharmacotherapy is mandatory to prevent acute pancreatitis
• TG 200–499 mg/dL: pharmacotherapy considered if ASCVD risk is elevated and lifestyle measures are insufficient
• TG < 200 mg/dL: focus on overall lipid management (statins for ASCVD risk reduction)

Drug Options

1. Fibrates (First-Line for TG ≥ 500 mg/dL)

• Mechanism: Activate PPARα → increased lipoprotein lipase activity → enhanced TG clearance; reduce hepatic VLDL synthesis
• Agents: Fenofibrate (preferred), gemfibrozil
• TG reduction: 30–50%
• Dose: Fenofibrate 145 mg/day orally
• Key considerations:
  • If combined with a statin, use fenofibrate (not gemfibrozil) — gemfibrozil inhibits statin glucuronidation, dramatically increasing myopathy/rhabdomyolysis risk (per ADA 2023 Guidelines, p. 21)
  • Monitor renal function and LFTs
  • Avoid in severe renal impairment

2. Prescription Omega-3 Fatty Acids (First-Line, especially TG ≥ 500 mg/dL)

• Agents:
  • Icosapentaenoic acid (EPA) only — Vascepa (icosapentaenoic acid 4 g/day): proven ASCVD risk reduction in REDUCE-IT trial (high-risk patients on statins)
  • EPA + DHA — Lovaza (omega-3 acid ethyl esters 4 g/day): TG lowering without proven ASCVD benefit; may modestly raise LDL-C
• TG reduction: 20–45% at 4 g/day
• Key point: Only pure EPA (icosapentaenoic acid) has demonstrated cardiovascular outcome benefit; EPA+DHA combinations do not share this benefit

3. Niacin (Extended-Release)

• TG reduction: 20–40%; also raises HDL-C
• Caveat: AIM-HIGH and HPS2-THRIVE trials showed no additional cardiovascular benefit when added to statin therapy; not routinely recommended for ASCVD risk reduction
• Use limited to refractory cases or when HDL raising is also desired
• Side effects: flushing, hepatotoxicity, hyperglycemia, hyperuricemia

4. Statins

• Primarily for LDL-C and ASCVD risk reduction, but high-intensity statins (atorvastatin, rosuvastatin) also reduce TG by 10–20%
• Use when TG elevation accompanies elevated LDL-C in high cardiovascular risk patients

Summary: Drug Selection by TG Level

Special Populations

Diabetes (per ADA/Comprehensive CV Risk Guidelines, p. 21)

• TG ≥ 500 mg/dL: pharmacotherapy mandatory (fibrate or prescription omega-3) to prevent pancreatitis
• Optimizing glycemic control is itself TG-lowering
• If on statin, add fenofibrate preferentially over gemfibrozil

Severe / Familial Hypertriglyceridemia (TG > 1000 mg/dL)

• Hospitalization may be needed if pancreatitis is present or imminent
• Strict fat-free diet (< 10–15% calories from fat)
• IV insulin infusion (activates lipoprotein lipase) — used in pancreatitis setting
• Plasmapheresis in extreme cases (TG > 2000 mg/dL with pancreatitis unresponsive to other measures)
• Volanesorsen (antisense oligonucleotide targeting apoC-III): approved for familial chylomicronemia syndrome

Pregnancy

• Dietary fat restriction is primary treatment; fibrates and statins are generally contraindicated
• Omega-3 fatty acids may be used cautiously
• Severe cases may require hospitalization

Monitoring

• Repeat fasting lipid panel 4–12 weeks after initiating therapy or dose adjustment
• Once stable, monitor every 6–12 months
• If on fibrate: check LFTs and creatinine at baseline and periodically
• If on combination statin + fibrate: monitor for myopathy (CK if symptomatic)

Key Takeaways

1. Always treat secondary causes first — diabetes, hypothyroidism, alcohol, and offending drugs are common reversible contributors.
2. Lifestyle modification (low-carb diet, alcohol cessation, weight loss, exercise) is highly effective and should always accompany pharmacotherapy.
3. TG ≥ 500 mg/dL requires prompt pharmacotherapy to prevent acute pancreatitis — fibrate or high-dose omega-3 are first-line.
4. Fenofibrate is preferred over gemfibrozil when combining with statins due to lower drug interaction risk.
5. Pure EPA (icosapentaenoic acid) is the only omega-3 formulation with proven ASCVD mortality benefit.